Oslo, Norway, 19 October 2023 – Circio Holding ASA (OSE: CRNA) today announces that an abstract describing its circular RNA technology has been accepted for poster presentation at the 30th i European Society for Gene and Cell Therapy in Brussels, Belgium.
The poster is scheduled for presentation 25-26 October 2023 and will be available on Circio’s website after the presentation.
|Poster title:||circVec, a versatile circular RNA vector cassette for enhanced and durable intra-cellular protein expression|
|Date and time:||Wednesday 25 October 2023, 17:00- 18:16 CEST and Thursday 26 October 2023, 20:30-21:30 CEST|
|Presenter:||Thomas Birkballe Hansen, VP and Head of Research, Erik Digman Wiklund, CEO|
About European Society of Gene and Cell Therapy
The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy, and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.
Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for rare disease, vaccines, and cancer. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed for many purposes. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems, and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials in RAS-mutated pancreatic cancer and multiple myeloma in the USA and Norway. These studies are being run through academic collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.